Valted Seq, Inc.

Valted Seq, Inc. specializes in neurodegenerative disease research, offering advanced analytics and precision therapeutics focused on conditions like Alzheimer's and Parkinson's diseases. Valted Seq, Inc. was founded in 2019 and operates from Gaithersburg, US.

The company focuses on the development of analytics and therapeutics for neurodegenerative diseases. It has completed a total of 2 deals, with its most recent funding round on November 2, 2021, during which it raised USD 10. 5 mn in a Seed round led by DongKoo Bio & Pharma Co. , Ltd.

alongside OV Principal Investments. The company's CEO is Mohammad Ranjbar. Valted Seq operates at the forefront of neurodegenerative disease research, featuring the world’s largest repository of single-cell sequencing data for diseases such as Alzheimer's and Parkinson's. Its primary products include advanced analytics and precision therapeutics aimed at identifying novel biomarkers for early detection and personalized treatment.

The company collaborates with leading medical institutions and biopharmaceutical companies across North America and Europe, serving a client base that includes academic researchers and pharmaceutical firms. Valted Seq's revenue model is based on collaborations with academic and commercial entities within the biopharmaceutical sector. The company generates income by providing access to its extensive database and analytics tools to research institutions and pharmaceutical companies developing innovative therapies. Transactions are primarily on a B2B basis, with clients subscribing to packages that offer varying access to data and analytical insights, tailored to meet diverse organizational needs.

In December 2021, Valted Seq, Inc. raised USD 10. 5 mn in Seed funding, led by DongKoo Bio & Pharma Co. , Ltd.

The funding will be utilized to accelerate the development of its HiF-Seq platform. The company aims to enhance its product offerings and expand its reach into new markets and geographic regions. Specific targets for growth have not been disclosed, but the recent funding is a strategic move to bolster their capabilities in neurodegenerative disease research.